Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Cutaneous Sarcomas
NCT07007273Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2025
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cutaneous sarcoma, sponsored by Moffitt Cancer Center. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
cutaneous sarcoma
Beyond the preview
Go deeper on NCT07007273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007273.